EGFR and non-small cell lung carcinoma: Patients with high CD73 expression (≥ 50%) on the tumor cells showed improved progression-free survival (PFS) and OS, particularly in EGFR-mutant NSCLC patients receiving immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and its ligand PD-L1 [164].